GUILHERME FIALHO DE FREITAS
Índice h a partir de 2011
1
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina - Médico
7 resultados
Resultados de Busca
Agora exibindo 1 - 7 de 7
conferenceObject High-dose chemotherapy with autologous stem cell transplant (HDCT) for patients (pts) with advanced germ-cell tumors (aGCT): Real-world evidence from a tertiary cancer center in Brazil.(2023) POLHO, Gabriel Berlingieri; CUNHA, Mateus Trinconi; XAVIER, Erick Menezes; SILVA, Jamile Almeida; HIDALGO FILHO, Cassio Murilo Trovo; CRUSOE, Nathalia de Souza Del Rey; ATANAZIO, Marcelo Junqueira; HORITA, Vivian; FREITAS, Guilherme Fialho de; MUNIZ, David Queiroz Borges; ROCHA, Vanderson Geraldo; MOTA, Jose Mauricio- Effects of Palliative Chemotherapy in Unresectable or Metastatic Colorectal Cancer Patients With Poor Performance Status(2023) ROCHA, Lucila Soares da Silva; MONIZ, Camila Motta Venchiarutti; SILVA, Marilia Polo Mingueti e; FREITAS, Guilherme Fialho de; SILVA, Virgilio Souza e; HOFF, Paulo Marcelo Gehm; RIECHELMANN, Rachel P.Chemotherapy's benefit in frail (ECOG PS 3 and 4) patients with metastatic colorectal cancer (mCRC) is uncertain. We evaluated symptom improvement, quality of life, clinical improvement, toxicity, response rate, improvement of ECOG PS, and overall survival in these patients. Multiagent chemotherapy improved symptoms in 42.8% without grade 3 to 4 toxicity, but 46% of patients presented early clinical deterioration. Palliative multiagent chemotherapy in poor-performance mCRC patients resulted in mild impact in symptoms with no benefit in OS and a high risk of toxicity and treatment-related death.Introduction: Colorectal cancer is the second most common cancer in both genders and often presents as a metastatic, unresectable, or recurrent disease in early follow-up. It is uncertain the benefit of oxaliplatin-based palliative chemotherapy (CT) in the first line of treatment in patients with compromised performance status (PS), Eastern Cooperative Oncology Group (ECOG) 3 and 4. These patients are systematically excluded from clinical trials but may be treated in clinical practice. Methods: We conducted a prospective observational cohort whose primary outcome was improving at least 2 points in the worst symptom in the Edmonton Symptom Assessment System Scale (ESAS-r), without grade 3 to 4 toxicity, comparing baseline and fourth week of treatment. Secondary endpoints included quality of life using the European Quality of Life-5 dimensions questionnaire, toxicity, response rate, clinical improvement of ECOG PS, and overall survival (OS). Results: We included 28 patients, and 12 (42.8%) achieved the primary endpoint. Median overall survival was 86 days, 46% of patients did not respond to the fourth-week reevaluation due to clinical deterioration, and 17.8% presented toxicity grade & GE;3, with 5 patients dying from toxicity. In addition, ECOG PS 4 or cholestasis had poorer overall survival. Finally, 25% and 53.6% of patients received these treatments in the last 14 and 30 days of life, respectively. Conclusion: In the present study, palliative multiagent chemotherapy in poor performance status patients with non-molecularly selected colorectal cancer tended to impact tumor symptoms control; however, there is no benefit in OS and a considerable risk of toxicity and treatment-related death.
conferenceObject Randomized phase II trial of neoadjuvant androgen deprivation therapy plus abiraterone and apalutamide for patients with high-risk localized prostate cancer: Pathologic response and PSMA imaging correlates.(2022) BASTOS, Diogo Assed; COELHO, Rafael; CARDILI, Leonardo; GALIZA, Felipe; ILARIO, Eder Nisi; VIANA, Ublio; MURTA, Claudio Bovolenta; GUGLIELMETTI, Giuliano; CORDEIRO, Mauricio; PONTES JR., Jose; MUNIZ, David Queiroz Borges; SILVA, Jamile Almeida; MOTA, Jose Mauricio; FREITAS, Guilherme Fialho De; LEITE, Katia Ramos Moreira; BUCHPIGUEL, Carlos Alberto; NAHAS, William CarlosbookPart Câncer de próstata(2023) MOTA, José Mauricio; MUNIZ, David Queiroz Borges; CRUSOé, Nathalia; FREITAS, Guilherme Fialho de- Rare intrascrotal tumors in a tertiary cancer center: A retrospective case series.(2022) CUNHA, Mateus Trinconi; CARDOSO, Camila; FREITAS, Guilherme Fialho de; SILVA, Jamile Almeida; MUNIZ, David Queiroz Borges; BASTOS, Diogo Assed; CARDILI, Leonardo; MOTA, Jose Mauricio
- Epidemiology and Outcomes of Patients With Brain Metastases From Colorectal Cancer-Who Are These Patients?(2021) BONADIO, Renata Colombo; FREITAS, Guilherme Fialho; BATISTA, Daniel Negrini; MOREIRA, Otavio Augusto Noschang; DIAS, Carla A. R.; CASTRIA, Tiago Biachi; SABBAGA, Jorge; HOFF, Paulo M.Brain metastases have been seen more frequently in the late course of colorectal cancer. In this large cohort, we showed that, despite the advances in systemic therapy, prognosis remains poor for patients who develop brain metastases. Aggressive local therapy should be considered for selected patients. Background: Brain metastases (BMs) from colorectal cancer (CRC) are unusual; however, an increase in incidence has been reported. The evidence available on the subject is scarce, and a better understanding is warranted. We aimed to characterize the epidemiology and the outcomes of patients with BMs from CRC. Patients and Methods: A cohort of patients with BMs from CRC was retrospectively evaluated. Patients were treated in a single center between May 2008 and April 2019. BMs were confirmed by brain computed tomography or magnetic resonance imaging. Results: A total of 247 consecutive patients were evaluated. Most patients had a left-sided primary tumor (193, 78%) and at least two extra-cranial metastatic sites (194, 78%). Ninety-six patients (39%) were RAS wild-type; 68 patients (27%) were RAS mutated; and 83 patients (34%) were not characterized. Median time from the initial diagnosis to BMs was 27.6 months (interquartile range, 13.1-46.9). Regarding local therapy, 43 patients (17.4%) were treated with BM surgery alone, 76 patients (30.8%) with radiotherapy (RT) alone, and 58 patients (23.5%) with both surgery and RT. Median overall survival (OS) was 2.9 months (95% confidence interval [CI], 2.2-3.5). Six-month and 1-year OS rates were 29% (95% CI, 23-25) and 13.5% (95% CI, 9.2-18.6), respectively. In a multivariable analysis, BM surgery alone (hazard ratio [HR], 0.56; P =.018), RT alone (HR, 0.51; P =.001), and surgery plus RT (HR, 0.27; P <.001) were associated with superior OS, whereas Eastern Cooperative Oncology Group Performance Status 3 or 4 (HR, 2.01; P =.009) and male gender (HR, 1.46; P =.012) were negative prognostic factors. RAS status was not associated with OS. Conclusion: BMs occur late during the course of colorectal cancer and are more common in patients with a left-sided primary tumor and a high volume of metastatic disease. BMs from colorectal cancer are still associated with an extremely poor prognosis; however, selected patients may benefit from treatment with surgical resection and radiotherapy.
bookPart Tumores de rim e bexiga(2023) FREITAS, Guilherme Fialho de; MUNIZ, David Queiroz Borges; MOTA, José Mauricio